JW Therapeutics drops 6% on discounted share placementMarket Movers·Nov 17, 2026 at 01:36 AM02126+4.39%
JW Therapeutics’ CAR-T Drug Enters China’s Reimbursement List With 78% Price Cut; Can Still Be Profitable, CEO SaysYicai·Nov 16, 2026 at 10:47 AM02126+4.39%
JW Therapeutics surges 13% as Carteyva added to NRDLMarket Movers·Nov 16, 2026 at 01:31 AM02126+4.39%
JW Therapeutics Agrees to HKD 160 Million Private Share PlacementPUBT·Nov 15, 2026 at 12:00 PM02126+4.39%
Carteyva Included in 2026 National Reimbursement Drug ListTip Ranks·Nov 15, 2026 at 10:40 AM02126+4.39%
JW Therapeutics Plans Presentation on Carteyva® NRDL InclusionTip Ranks·Nov 15, 2026 at 10:39 AM02126+4.39%
JW Therapeutics Expects Carteyva Unit Manufacturing Costs to Fall More Than 65%PUBT·Nov 15, 2026 at 10:16 AM02126+4.39%
JW Therapeutics climbs 6% on liver cancer TCR-T project transferMarket Movers·Nov 10, 2026 at 01:32 AM02126+4.39%
JW THERAP-B Transfers Licensed Assets to Eureka for USD10 million Upfront PaymentAASTOCKS News·Nov 10, 2026 at 01:25 AM02126+4.39%
JW Therapeutics Announces Proposed Eureka Asset Transfer and Licensing DealTip Ranks·Nov 9, 2026 at 03:10 PM02126+4.39%
Weekly Recap | JW THERAP-B +12.61%, rise and fade this weekWeekly Review·Nov 7, 2026 at 05:41 AM02126+4.39%
A USD 90 Million Upfront Anchors Hong Kong Biotech's December RushGlobal Report·Oct 28, 2026 at 03:45 AM02269-3.67%02268-2.97%